Kärkinen Juho, Sorakunnas Eero, Miettinen Päivi J, Raivio Taneli, Hero Matti
New Children's Hospital, Pediatric Research Center, Helsinki University Hospital, Helsinki, Finland.
Department of Physiology, Medicum Unit, Faculty of Medicine, and Stem Cells and Metabolism Research Program, Research Programs Unit, University of Helsinki, Helsinki 00014, Finland.
EClinicalMedicine. 2021 Nov 20;42:101208. doi: 10.1016/j.eclinm.2021.101208. eCollection 2021 Dec.
Extremely tall children (defined as height SDS (HSDS) ≥+3) are frequently referred to specialized healthcare for diagnostic work-up. However, no systematic studies focusing on such children currently exist. We investigated the aetiology, clinical features, and auxological clues indicative of syndromic tall stature in extremely tall children subject to population-wide growth monitoring and screening rules.
Subjects with HSDS ≥+3 after three years of age born between 1990 and 2010 were identified from the Helsinki University Hospital district growth database. We comprehensively reviewed their medical records up to December 2020 and recorded underlying diagnoses, auxological data, and clinical features.
We identified 424 subjects (214 girls and 210 boys) who fulfilled the inclusion criteria. Underlying growth disorder was diagnosed in 61 (14%) patients, in 36 (17%) girls and 25 (12%) boys, respectively (P=0•15). Secondary causes were diagnosed in 42 (10%) patients and the two most frequent secondary diagnoses, premature adrenarche, and central precocious puberty were more frequent in girls. Primary disorder, mainly Marfan or Sotos syndrome, was diagnosed in 19 (4%) patients. Molecular genetic studies were used as a part of diagnostic work-up in 120 subjects. However, array CGH or next-generation sequencing studies were seldom used. Idiopathic tall stature (ITS) was diagnosed in 363 (86%) subjects, and it was considered familial in two-thirds. Dysmorphic features or a neurodevelopmental disorder were recorded in 104 (29%) children with ITS. The probability of a monogenic primary growth disorder increased with the degree of tall stature and deviation from target height.
A considerable proportion of extremely tall children have an underlying primary or secondary growth disorder, and their risk is associated with auxological parameters. Clinical features related to syndromic tall stature were surprisingly frequent in subjects with ITS, supporting the view that syndromic growth disorders with mild phenotypes may be underdiagnosed in extremely tall children. Our results lend support to comprehensive diagnostic work-up of extremely tall children.
Päivikki and Sakari Sohlberg Foundation, Foundation for Pediatric Research, and Helsinki University Hospital research grants.
极高的儿童(定义为身高标准差评分(HSDS)≥+3)经常被转诊至专科医疗保健机构进行诊断检查。然而,目前尚无针对此类儿童的系统性研究。我们调查了在全人群生长监测和筛查规则下,极高儿童中导致综合征性高身材的病因、临床特征及体格学线索。
从赫尔辛基大学医院区生长数据库中识别出1990年至2010年出生、三岁后HSDS≥+3的受试者。我们全面回顾了他们截至2020年12月的病历,并记录了潜在诊断、体格学数据及临床特征。
我们识别出424名符合纳入标准的受试者(214名女孩和210名男孩)。61名(14%)患者被诊断为潜在生长障碍,其中女孩36名(17%),男孩25名(12%)(P=0.15)。42名(10%)患者被诊断出继发原因,最常见的两个继发诊断——肾上腺功能早现和中枢性性早熟在女孩中更常见。19名(4%)患者被诊断为原发性疾病,主要是马凡综合征或索托斯综合征。120名受试者的诊断检查中使用了分子遗传学研究。然而,很少使用阵列比较基因组杂交(array CGH)或下一代测序研究。363名(86%)受试者被诊断为特发性高身材(ITS),其中三分之二被认为是家族性的。104名(29%)ITS儿童记录有畸形特征或神经发育障碍。单基因原发性生长障碍的可能性随身材高度及与目标身高的偏差程度增加。
相当一部分极高儿童存在潜在的原发性或继发性生长障碍,其风险与体格学参数相关。在ITS受试者中,与综合征性高身材相关的临床特征出人意料地常见,这支持了这样一种观点,即具有轻度表型的综合征性生长障碍在极高儿童中可能未被充分诊断。我们的结果支持对极高儿童进行全面的诊断检查。
派维姬和萨卡里·索尔伯格基金会、儿科研究基金会及赫尔辛基大学医院研究基金。